Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to examine the effectiveness the selective serotonin reuptake
inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to
self-harm and actual self-harming among young adults with borderline personality disorder who
are also currently depressed. Subjects will receive either escitalopram or placebo for eight
weeks. During this time subjects will be make weekly visits to see the psychiatrist and
record their thoughts and feelings several times each day using an electronic diary.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborators:
Northwestern University Temple University University of Southern Mississippi